cyrilzakka/clinical-trials huggingface dataset:
Contrast-Enhanced Intraoperative Ultrasound During Liver Surgery for Colorectal Cancer Liver Metastases

Contrast-enhanced intraoperative ultrasound (CE-IOUS) during surgery for colorectal liver metastases (CLM) has become a part of clinical practice. However, if it should be selectively or routinely applied remains unclear. This study is carried out to clarify which are the criteria for a selective use of CE-IOUS if any.

Contrast-enhanced intraoperative ultrasound (CE-IOUS) during surgery for colorectal liver metastases (CLM) is entered in clinical practice. However, its impact seems to decrease with the improvement of preoperative imaging. Therefore, if CE-IOUS should be selectively or routinely applied remains unclear: a profile of patients who may benefit of CE-IOUS application has to be disclosed. The aim of this study is to define reliable criteria for a selective use of CE-IOUS during surgery for CLM. IOUS is performed using 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging is completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist. Ultrasound guidance is used to drive the dissection plane as previously described. Reference standards are histology and imaging at 6 months after surgery. Univariate and multivariate analyses are performed. Statistical significance is set at P=0.05.

Eligibility Criteria:
Inclusion Criteria:

* consecutively enrolled patients with CLM who underwent surgery and during this procedure received IOUS and CE-IOUS.
* each patient had at least 6 months of postoperative follow-up.

Exclusion Criteria:

* patients who after IOUS and CE-IOUS had explorative laparotomy only were excluded from the analysis since there was no histological confirmation of the tumor and most of them were lost to surgical follow-up
Body Awareness in Dentistry Students and Working Dentists

The current study aims to comparison the body awareness and musculoskeletal problems of 1st dentistry students, intern students and working dentists and also investigate the factors affecting the body awareness over the years in dentistry profession.

Dentists also have the highest prevalence among the occupational groups providing health services. More than 60% of dentists have pain in at least one of their body parts.Pain due to musculoskeletal disorders can affect body awareness of person have chronic pain. Body awareness is known as the capacity to distinguish body parts and has an important role in promoting well-coordinated movements. The current study aims to comparison the body awareness and musculoskeletal problems of 1st dentistry students, intern students and working dentists and also investigate the factors affecting the body awareness over the years in dentistry profession.

Eligibility Criteria:
Inclusion Criteria:

* The inclusion criteria are being between the ages of 18 and 65 and had been practising dentistry for more than two years for dentists group.

Exclusion Criteria:

* The exclusion criteria are had a surgical history of vertebral column or any neurological or inflammatory disorders or trauma history.
Effect of the Laparoscopic Approach in Reducing Postoperative Severe Complications Following Hepatectomy for Colorectal Liver Metastases

The objective of this study is to demonstrate the superiority of the laparoscopic approach over the open approach in the resection of colorectal liver metastases, by examining the reduction of postoperative complications (including mortality), measured using the Comprehensive Complication Index (CCI) within 90 days of the procedure or regardless of the date during the hospital stay.

While laparotomy is still the standard approach of resectable colorectal liver mestastases, its associated morbidity remains non-negligible with reported mortality and complications rates ranging from 2 to 8% and 30 to 70%, respectively (1). Besides the underlying liver disease together with the comorbidities of the patients, this high morbidity is also related to the type of surgical approach. Since less than 15% of liver resections are currently performed using the laparoscopic approach in France, a trial showing the superiority of the laparoscopic approach in comparison to the open approach for patients with colorectal liver metastases qualifying for both approaches would allow improving management of patients, reducing the length of stay, maybe decreasing the global cost and changing current practices on a national scale.

In order to demonstrate the superiority of the laparoscopic approach over the laparotomy approach, patients with colorectal hepatic metastasis will be randomly assigned to either the laparoscopy or laparotomy groups. Post-operative complications (including mortality) will be measured using the Comprehensive Complication Index (CCI) within 90 days postoperatively or at any time during hospitalization. The participation time for each patient in the study is 3 years, the patient will be followed at 1, 3, 6, 9, 9, 12, 15, 18, 21, 24, 30 and 36 months.

Eligibility Criteria:
Inclusion Criteria:

* Presenting with colorectal liver metastases requiring liver resection ± concomitant radiofrequency ablation.
* Qualifying for both a laparoscopic approach and an open approach.
* Informed written consent.
* Affiliated to health insurance regimen.

Exclusion Criteria:

* Hybrid liver resection (including both laparoscopic and open resection).
* Liver resection requiring an associated vascular or biliary reconstruction.
* Contraindication to surgery.
* Contraindication to laparoscopy (pneumoperitoneum).
* ASA (American Society of Anesthesiologists) score IV or V or life expectancy \< 3 months.
* Poor comprehension of French language or cognitive impairment
* Pregnancy or breastfeeding.
* Patient under guardianship or unable to give consent
* People particularly protected by French law.
Persistence Disease After Laparoscopic Shaving of Rectal Endometriosis

When performing shaving of a rectal endometriotic nodule, the surgeon can use the macroscopic appearance of the nodule and the tactile feedback provided by the laparoscopic instruments to decide the area of the bowel that needs to be excised. Theoretically, compared with segmental bowel resection, the shaving technique may expose the patients to a higher risk of persistence of intestinal endometriosis. The objective of this ultrasonographic study was to assess the risk of rectal endometriosis persistence following laparoscopic shaving of rectovaginal nodules.


Eligibility Criteria:
Inclusion Criteria:

* patients underwent laparoscopic shaving of rectovaginal endometriosis infiltrating the rectum

Exclusion Criteria:

* patients underwent previous bowel surgery (except appendectomy);
* patients experienced postoperative complications (such as pelvic abscess, rectovaginal fistula, ureteral injuries)
Fusariosis in Solid-Organ Transplant Recipients

This exempt chart review study will try to determine the clinical presentation, prognostic factors, response to different treatment modalities and mortality among patients diagnosed with fusariosis after solid-organ transplantation.

This exempt chart review study will try to determine the clinical presentation, prognostic factors, response to different treatment modalities and mortality among patients diagnosed with fusariosis after solid-organ transplantation.This will help determine prognostic factors, response to different treatment modalities and mortality among patients diagnosed with fusariosis after solid-organ transplantation.

Eligibility Criteria:
Inclusion Criteria:

* Solid-organ transplants (liver, kidney, lung, heart, pancreas, small bowel transplant) diagnosed with fusariosis or infections due to Fusarium, species in our institution

Exclusion Criteria:

* Those subjects that do not meet inclusion criteria
The Value of Supervised Exercise Therapy After Invasive Treatment of Peripheral Arterial Disease

The objective of this study is to investigate what the value is of SET after a radiological or surgical intervention for peripheral arterial disease in the aorto-iliacal, femoro-popliteal and crural segments in comparison with a control group.

Treatment of peripheral arterial disease consists of vascular risk factor management and, dependent on the severity of the disease, exercise therapy, and either radiological or surgical intervention. After invasive treatment, many patients keep complaints, or complaints return, despite the fact that the treated segment is still patent.

Supervised exercise therapy (SET) has been proved to be an effective treatment for patients with intermittent claudication, with a significant increase in maximal walking distance. Further, exercise therapy contributes to an improvement in quality of life, a delay in disease progression and an improvement of the vascular risk profile.

Research on SET after an invasive intervention is rare. In one study, the effect of SET after surgical treatment on walking distance was determined. The initial claudication distance increased significantly in the exercise group, compared with surgical treatment alone.

In June 2004, the Network for Exercise Therapy Parkstad (NETP) was implemented in Heerlen and its environs. The physiotherapists of this network provide community based SET according to the protocol of the Royal Dutch Society of Physiotherapy. The web based database, which is a part of the NETP, was retrospectively searched for patients who started SET within 2 months after a radiological or surgical intervention. Seventeen patients fulfilled these criteria, and after 1, 3, 6 and 12 months, there was a significant increase in both initial claudication distance (ICD) and absolute claudication distance (ACD).

The expectation is that SET, immediately offered after an invasive intervention for peripheral arterial disease, influences walking distance and quality of life. Further, a positive influence on vascular risk factors and the frequency of re-interventions is expected.

Eligibility Criteria:
Inclusion Criteria:

* PAD stage 2 or 3 according to Fontaine,
* Surgical or radiological intervention indicated

Exclusion Criteria:

* No insurance for physiotherapy,
* Insufficient command of the Dutch language,
* Serious cardiopulmonary limitations (NYHA 3-4,)
* Major amputation,
* Serious co-morbidity prohibiting physical training
Retinal Pigment Epithelium Safety Study for Patients in B4711001

This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.


Eligibility Criteria:
Inclusion Criteria:

* Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
* Previous participation in Protocol B4711001 and received treatment with PF-05206388.
* Subjects who are willing and able to comply with scheduled visits, and study procedures.

Exclusion Criteria:

* there are no exclusion criteria
Trial of a Novel Family-Based Intervention to Increase Outdoor Time and Fitness

This study aims to implement a new family-based health behavior community program to increase time spent outdoors and physical activity among Singapore children aged 6 to 12 years in a 1-year randomized clinical trial. 300 children from 250 families will be randomly assigned to either a family-based intervention or no intervention. The family-based intervention comprises structured weekend outdoor activities organized by National Parks and incentives for children to wear a pedometer and increase their daily steps. Families who meet their monthly step and outdoor activity goals will receive a range of prizes and incentives. Both groups will receive brochures on the National Myopia Prevention Program and physical activity. The success of the intervention will be evaluated through light meters, 7-day outdoor diaries, questionnaires documenting outdoor time and myopia; as well as pedometer steps, walking tests, and body mass index. A community-based intervention will be developed to improve the health of Singapore children by increasing outdoor time and physical activity to prevent myopia and obesity.

To develop, implement, and evaluate a novel incentive-based family intervention to increase time spent outdoors and physical activity among children aged 6 to 12 years in a 1-year randomized controlled trial.

Eligibility Criteria:
Inclusion Criteria:

* Children between 6 and 12 years of age with no known health problems preventing them from staying outdoors or walking for physical activity will be included as long as they are Singapore citizens or permanent residents.
* Both myopic and non-myopic children will be included

Exclusion Criteria:

* Children with medical conditions such as Type 1 diabetes, severe asthma, cancer or mental illness will be excluded.
Effects of Amitriptyline for the Treatment of Pain on Driving Performance and Cognition.

The acute and subchronic effects of amitriptyline were compared to placebo in a double-blind crossover randomized study on driving ability and driving-related skills in chronic neuropathic pain patients.It was hypothesized that nocturnally administered 25 mg amitriptyline might affect driving performance negatively after acute, but not after subchronic treatment.

The present study was designed to determine the effects of nocturnally administered 25 mg amitriptyline, compared to placebo, after single (Day 1, acute effects) and repeated (Day 15, subchronic effects) administration on driving performance in neuropathic pain patients. In addition to the on-the-road driving test, laboratory tests measuring driving-related skills were administered. Moreover, effects of amitriptlyine on an attentional capacity task were tested using Event-Related Potentials (ERPs). It was hypothesized that nocturnally administered 25 mg amitriptyline might affect driving performance negatively after acute, but not after subchronic treatment.

Eligibility Criteria:
Inclusion Criteria:

* age, amitriptyline responder, adequately treated with amitriptyline in studied dose before study participation, pain intensity score (VAS) of at least 4 cm on a 10 cm scale, driving licence, driving experience, speak fluently Dutch, normal vision, right-handed

Exclusion Criteria:

* psychological or physical disorder other than pain(-related), other psychotropic medication use, excessive drinking or smoking, alcohol- or drug dependence, illigal drug use
Fertility Preservation in Transgender Persons: a Retrospective Look

Patients in this study will be asked how they feel about the decision to freeze gametes, using a validated questionnaire. In addition, a number of questions with free text fields will be included in the questionnaire to write down any reasons for their satisfaction or regret. In a second part, the intention to use the frozen material will be assessed. We focus on techniques with real perspectives (e.g. cryopreservation of oocytes and sperm cells) and not on techniques that are more experimental for later use (cryopreservation of ovarian and testicular tissue).


Eligibility Criteria:
Inclusion Criteria:

* Dutch speaking
* Sperm or oocyte preservation between june 2015 and june 2020. Survey in 2021

Exclusion Criteria:

* Ovarian and testicular tissue cryopreservation
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy) subjects. The study will also assess the safety and tolerability of pramlintide administered by SC infusion or injection.


Eligibility Criteria:
Inclusion Criteria:

* Is \<6'3" (190.5 cm) tall and weighs \<300 lb (\~136.3 kg)
* Is obese with a body mass index (BMI) \>=30 kg/m\^2 to \<=45 kg/m\^2 and with a history consistent with progressive weight gain and development of obesity not secondary to drastic or traumatic initiating events (e.g., excessive weight gain due to cessation of smoking)
* Is a nonsmoker (never smoked or has not smoked for at least 2 years)
* Does not have a clinical diagnosis of diabetes
* Has not had a major change in daily physical activity within 2 months prior to study start (e.g., initiation of an exercise program)
* Usually consumes three major meals (morning, midday, and evening) each day and rarely (less than once a week) wakes up to eat during the night

Exclusion Criteria:

* Is currently enrolled in a weight loss program or plans to enroll in a weight loss or exercise program within the next 3 months
* Is currently treated or expected to require or undergo treatment or has been treated within 2 months before screening with medications that are excluded:

  * Over the counter antiobesity agents including herbal supplements or prescription antiobesity agents approved for the long-term (including orlistat \[Xenical\] and sibutramine \[Meridia\]) and the short-term (including phentermine \[Adipex-P, Celltech, Pro-Fast SA, Pro-Fast SR, Fastin, Oby trim, Zantryl, Teramine, Phentride, Phentercot, Obephen, Oby-cap\], mazindol \[Sanorex and Mazanor\], methamphetamine \[Desoxyn\], diethylpropion \[Tenuate and Tenuate Dospan\], phendimetrazine \[Bontril, Prelu-2, Melfiat 105, Unicelles, X-Trozine, Plegine, Adipost, Obezine, Phendiet-105, PT 105\] and benzphetamine \[Didrex\]) treatment of obesity
  * Systemic steroids by oral, intravenous, or intramuscular route or potent topical steroids that are known to result in high systemic absorption
  * Alpha- or Beta-Blockers, centrally acting sympathicolytic or sympathicomimetic agents, reserpin, guanethidine, etc.
  * Psychotropic medications (e.g., tricyclic antidepressants, monoamine oxidase \[MAO\] inhibitors, selective serotonin reuptake inhibitors \[SSRIs\], neuroleptics, lithium, and benzodiazepines)
  * Hypnotic-sedative medications or medications that may affect sleeping behavior including medications containing caffeine
  * Drugs that directly affect gastrointestinal motility, including but not limited to: metoclopramide (Reglan®) and cisapride (Propulsid®); and macrolide antibiotics such as erythromycin and newer derivatives
* Has received any investigational drug within 3 months before study start
* Has participated previously in a study using pramlintide
Financial Health Incentives to Promote Physical Activity Among Hospital Employees: A Randomized Control Trial

The objective of this randomized control trial is to examine whether incentives-for-steps (i.e. $1 per day step count goals are reached) increase daily step counts among physically inactive hospital employees.

A 24-week, parallel arm, randomized control trial will be employed to examine the impact of incentives on physical activity among physically inactive Hamilton Health Science Corporation employees. Participants will be randomly allocated (1:1) into control (i.e. wellness program and accelerometer) or intervention groups (i.e. wellness program, accelerometer, incentives), where only intervention participants will receive reward points for completing daily step count goals.

After randomization, a baseline 'run-in' assessment phase will occur one week prior to the study intervention (T0). During this 'run-in' period, participants will wear a Bluetooth enabled StepsCount Piezo accelerometer, which will track participants' daily steps and moderate to vigorous physical activity (MVPA), and synchronize their accelerometer (i.e. upload information) to the Change4Life program for seven days. Participants will also be asked to complete the Behavioural Regulation to Exercise Questionnaire (BREQ-3) and the Self-Efficacy for Exercise Scale.

Throughout the 24-week study, all participants will be asked to wear the accelerometer and synchronize it to the Change4Life program daily. Date, steps per day, and bout minutes of MVPA per day (bouts include 10 or more continuous minutes of MVPA) will be collected when the accelerometer is synchronized. Daily synchronization from the accelerometer to the Change4Life program must be completed by 10 am the next morning. Participants will be instructed to increase their daily step counts by 1,000 and 2,000 steps above baseline (T0) over the course of the first six weeks of the study. On week 7, participants will be asked to increase daily steps per day to 3,000 over baseline, and maintain that level of activity for the duration of the study.

Outcome measures will be assessed at baseline (T0), intervention end point (T2), and follow up (T3).

Eligibility Criteria:
Inclusion Criteria:

* Over the age of 18 years
* English speaking

Exclusion Criteria:

* Existing medical condition, which could be exacerbated by physical activity as measured by the Physical Activity Readiness Questionnaire.

Note. Participants cannot enrol in the study without Internet access
Decision Aid for Dementia Therapies

The purpose of this study is to develop a decision aid to support patients and families making decisions about medications for dementia.


Eligibility Criteria:
Inclusion Criteria:

Patients:

* UCHealth patient
* Ages 18 y/o and above
* Documented neurocognitive deficits suggestive of mild cognitive impairment or early dementia as determined by their treating clinician.
* English or Spanish speaking

Caregiver:

* Ages 18 y/o and above
* Identified by the study participant as the person who helps the most with their medical care outside the hospital or clinic.
* English or Spanish speaking

Clinicians:

* Neurologists, primary care clinicians, pharmacists, or psychologists involved in dementia decision-making.
* English or Spanish speaking

Exclusion Criteria:

Patients:

* Not English or Spanish-speaking
* Neurocognitive deficits suggestive of moderate or severe cognitive impairment or late stage dementia.
* Not able to consent for themselves

Caregiver:

* Ages 17 y/o and below
* Not English or Spanish-speaking

Clinicians:

* Neurologists, primary care clinicians, pharmacists, or psychologists involved in dementia decision-making.
* English or Spanish-speaking
Improving Aspirin Prescription Rates in Outpatient Clinic

Ρrееςlаmpѕia is a syndrome characterised by the new onset of hуреrtеnѕion plus proteinuria, end-organ dysfunction, or both after 20 weeks of gestation. It complicates 3-5% of pregnancies.

Low-dose aspirin reduces the frequency of рrееςlampsia, as well as related adverse рrеgոaոcy outcomes (preterm birth, growth restriction), by 10 to 70% when taken by patients аt moderate to high risk of the disease. It has an excellent maternal/fetal safety profile. Thus, it is a reasonable preventive strategy for these patients.

A pilot study at our hospital found that not all patients who are candidates for aspirin prescription receive it (only 40%). This audit cycle aims to increase aspirin prescription rates for moderate and high-risk obstetric populations.


Eligibility Criteria:
Inclusion Criteria:

Women at high risk are those with any of the following:

1. hypertensive disease during a previous pregnancy
2. chronic kidney disease
3. autoimmune disease such as systemic lupus erythematosus or antiphospholipid syndrome
4. type 1 or type 2 diabetes
5. chronic hypertension.

Women with more than one moderate risk factor, such as are:

1. nulliparity
2. age 40 years or older
3. pregnancy interval of more than 10 years
4. body mass index (BMI) of 35 kg/m2 or more at first visit
5. family history of pre-eclampsia
6. multi-fetal pregnancy.

Exclusion Criteria:

* None. All eligible candidates will be included.